With biotechs in the political crosshairs, is now the time to look at the space? With Michael Yee, RBC Capital biotech analyst.
The "Halftime Report" traders give their final trades of the show.
The "FMHR" traders reveal their final trades, including Lending Club and Amgen.
The "FMHR" traders; Sarat Sethi, Douglas C. Lane & Associates; and Stephanie Link, TIAA Global Asset Management, reveal their final trades, including CVS, Square and more.
Biotech is rallying, and the bounce will continue, two technical analysts say.
As biotech stocks rally, Chad Morganlander, Stifel Nicolaus, and Jonathan Krinsky, MKM Partners, share their take on the biotech sector.
Goldman Sachs sent it's quarterly review of earnings season to clients this week. It had some surprising contrarian conclusions.
Wharton professor Jeremy Siegel predicted that the market would rally, here's what he sees next.
Goldman Sachs believes the S&P 500 will end the year at 2,100, and it's deploying three strategies to navigate the pullback, David Kostin said.
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
Ronny Gal, Sanford C. Bernstein, discusses the potential of a takeover deal for Biogen.
The "Fast Money" traders discuss their views on Biogen.
CVS Health's new "excluded" list includes medications used in treatment of patients with cancer, diabetes and hepatitis C.
Biogen and Ionis Pharmaceuticals soar on a new muscle-disorder drug for babies, CNBC's Meg Tirrell reports. The "Fast Money Halftime Report" traders weigh in.
With new questions emerging about the strength of the economy, will there be a potential cut in dividends? The "Fast Money Halftime Report" traders discuss.
CNBC's Brian Sullivan and the Options Action traders discuss the stocks they'll be watching next week.
A bionic biotech trade, as Amgen hits its 2016 high, with CNBC's Brian Sullivan and the Options Action traders.
AbbVie's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.
"Power Lunch" host Brian Sullivan looks at stocks with analyst recommendations, including Amgen and Dunkin Donuts.